Washington, D.C. 20549


Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Francois Cedric

(Last) (First) (Middle)


(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Apellis Pharmaceuticals, Inc. [ APLS ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
X Officer (give title below) Other (specify below)
Chief Executive Officer
3. Date of Earliest Transaction (Month/Day/Year)
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 06/27/2019 M 275,000 A $2.14 989,288 D
Common Stock 234,411 I See Footnote(1)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (Right to Buy) $2.14 06/27/2019 M 275,000 (2) 05/12/2020 Common Stock 275,000 $0 193,823 D
Explanation of Responses:
1. The securities are held by The Francois-DuBois Educational Trust (the "Trust"), for which Fiduciary Trust Company of New England serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.
2. This option was granted on May 12, 2010 and is fully vested.
/s/ David Watson, attorney-in-fact for Cedric Francois 07/01/2019
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Know all by these presents, that the undersigned hereby 
makes, constitutes and appoints each of David Watson and 
Timothy Sullivan, signing singly and each acting 
individually, as the undersigned's true and lawful 
attorney-in-fact with full power and authority as 
hereinafter described to: (1) execute for and on behalf 
of the undersigned, in the undersigned's capacity as an 
officer and/or director of Apellis Pharmaceuticals, Inc. 	
(the ?Company?), Forms 3, 4, and 5 (including any 
amendments thereto) in accordance with Section 
16(a) of the Securities Exchange Act of 1934 and 
the rules thereunder (the ?Exchange Act?); (2) do 
and perform any and all acts for and on behalf of 
the undersigned which may be necessary or desirable 
to prepare, complete and execute any such Form 3, 
4, or 5, prepare, complete and execute any 
amendment or amendments thereto, and timely 
deliver and file such form with the United States 
Securities and Exchange Commission and any stock 
exchange or similar authority; (3) seek or 
obtain, as the undersigned?s representative and 
on the undersigned?s behalf, information regarding 
transactions in the Company?s securities from any 
third party, including
 brokers, employee benefit 
plan administrators and trustees, and the 
undersigned hereby authorizes any such person to 
release any such information to such attorney-in-fact 
and approves and ratifies any such release of 
information; and (4) take any other action of any 
type whatsoever in connection with the foregoing 
which, in the opinion of such attorney-in-fact, 
may be of benefit to, in the best interest of, or 
legally required by, the undersigned, it being 
understood that the documents executed by such 
attorney-in-fact on behalf of the undersigned 
pursuant to this Power of Attorney shall be in 
such form and shall contain such terms and 
conditions as such attorney-in-fact may approve 
in such attorney-in-fact's discretion. The 
undersigned hereby grants to each such 
attorney-in-fact full power and authority to 
do and perform any and every act and thing whatsoever 
requisite, necessary, or proper to be done in the 
exercise of any of the rights and powers herein 
granted, as fully to all intents and purposes as 
the undersigned might or could do if personally 
resent, with full power of substitution or revocation, 
hereby ratifying and confirming all that such 
attorney-in-fact, or such attorney-in-fact's 
substitute or substitutes, shall lawfully do or 
cause to be done by virtue of this power of attorney 
and the rights and powers herein granted.  The 
undersigned acknowledges that the foregoing 
attorneys-in-fact, in serving in such capacity at 
the request of the undersigned, are not assuming 
nor relieving, nor is the Company assuming nor 
relieving, any of the undersigned's responsibilities 
to comply with Section 16 of the Exchange Act.  The 
undersigned acknowledges that neither the Company 
nor the foregoing attorneys-in-fact assume (i) any 
liability for the undersigned?s responsibility to 
comply with the requirement of the Exchange Act, 
(ii) any liability of the undersigned for any failure 
to comply with such requirements, or (iii) any 
obligation or liability of the undersigned for profit 
disgorgement under Section 16(b) of the Exchange Act. 
This Power of Attorney shall remain in full force and 
effect until the undersigned is no longer required to 
file Forms 3, 4, and 5 with respect to the undersigned's 
holdings of and transactions in securities issued by 
the Company, unless earlier revoked by the undersigned 
in a signed writing delivered to the foregoing 
attorneys-in-fact. IN WITNESS WHEREOF, the undersigned 
has caused this Power of Attorney to be executed as of 
this 6th day of November, 2017.       
Cedric Francois      Print Name